Outcomes
Alzheimer’s, Alzheimer’s Disease Assessment Scale
BRAIN
The primary outcome was change in the score on the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog11) from baseline to 48 weeks. The ADAS-Cog11 score is a validated outcome measure used in clinical trials of Alzheimer’s. It includes 11 tasks that include both subject-completed tests and observer-based assessments. Together these tasks assess the cognitive domains of memory, language, and praxis [Secondary outcomes included changes from baseline to 48 weeks by the Clinician Interview-Based Impression of Change Incorporating Caregiver Information (CIBIC+; range, 0 to 7, with higher scores indicating greater impairment) [The changes from baseline to 48 weeks in cerebral perfusion by single-photon emission computed tomography (SPECT), lower cerebral perfusion in the posterior emporoparietal regions which is relevant to the physiology of AD [The clinical outcomes were measured at baseline, 24 and 48 weeks. Brain perfusion and hippocampal volume were measured at baseline and 48 weeks.